23andMe Phase 1 Trial is an Immunotherapy for treating advanced solid tumors
A new Phase 1 Immunotherapy trial using genetic sequencing to address patients with metastatic solid tumors.
A new Phase 1 Immunotherapy trial using genetic sequencing to address patients with metastatic solid tumors.
If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.
**A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**